Back to resultsPre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Primary Purpose
Relapsed or Refractory Multiple Myeloma
Status
No longer available
Phase
Locations
International
Study Type
Expanded Access
Intervention
Talquetamab
Sponsored by
About this trial
This is an expanded access trial for Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sites / Locations
- DUMMY
- DUMMY
- DUMMY
- DUMMY
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT05503550
First Posted
August 12, 2022
Last Updated
September 13, 2023
Sponsor
Janssen Research & Development, LLC
1. Study Identification
Unique Protocol Identification Number
NCT05503550
Brief Title
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Official Title
Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma
Study Type
Expanded Access
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Janssen Research & Development, LLC
4. Oversight
5. Study Description
Brief Summary
The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Relapsed or Refractory Multiple Myeloma
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Talquetamab
Other Intervention Name(s)
JNJ-64407564
Intervention Description
Talquetamab will be administered subcutaneously (SC).
10. Eligibility
Minimum Age & Unit of Time
18 Years
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Janssen Research & Development, LLC Clinical Trial
Organizational Affiliation
Janssen Research & Development, LLC
Official's Role
Study Director
Facility Information:
Facility Name
DUMMY
City
Dummy
ZIP/Postal Code
99999
Country
Belgium
Facility Name
DUMMY
City
Dummy
ZIP/Postal Code
99999
Country
Iceland
Facility Name
DUMMY
City
Dummy
ZIP/Postal Code
99999
Country
Portugal
Facility Name
DUMMY
City
Dummy
ZIP/Postal Code
99999
Country
Slovenia
12. IPD Sharing Statement
Learn more about this trial
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
We'll reach out to this number within 24 hrs